ストックスクリーナーアプリを入手
1.61
7.33%
0.11
プレマーケット:
1.63
0.02
+1.24%
前日終値:
$1.50
開ける：
$1.51
24時間の取引高:
6.13M
Relative Volume:
1.00
時価総額：
$500.07M
収益：
$160.03M
当期純損益:
$-128.58M
株価収益率:
-3.7723
EPS:
-0.4268
ネットキャッシュフロー:
$-121.21M
1週間 パフォーマンス:
-4.17%
1か月 パフォーマンス:
+17.52%
6か月 パフォーマンス:
-17.01%
1年 パフォーマンス:
+8.78%
1日の値動き範囲:
$1.50
$1.68
1週間の範囲:
$1.48
$1.72
52週間の値動き範囲:
$1.09
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.61 | 500.07M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
94.40 | 164.43B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
327.11 | 125.40B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
82.39 | 105.46B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.99 | 66.87B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.33 | 52.59B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-06 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Pacific director Christopher M. Smith resigns from board - TradingView
[8-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Reports Material Event - Stock Titan
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - TradingView
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth - TradingView
Here's Why You Should Add PacBio Stock to Your Portfolio Now - Yahoo Finance
Pacific Biosciences updates its sequencing strategy. Investors watch long-read technology - AD HOC NEWS
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Is Pacific Biosciences (PACB) The Best Rising Penny Stock? - Insider Monkey
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 2500 Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 2000 Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000E Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000 Growth Benchmark - marketscreener.com
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions - Yahoo Finance
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences of California, Inc. Actuals & Estimates (NASDAQ:PACB) - TradingView
PACIFIC BIOSCIENCES OF CALIFORNIA ROE % Adjusted to Book Val - GuruFocus
Enterprise value to revenue forward of Pacific Biosciences of California, Inc. – FWB:P09 - TradingView
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – FWB:P09 - TradingView
PACB Forecast — Price Target — Prediction for 2027 - TradingView
PACB Stock Gains Focus As New Sequencing Tech Slashes Genome Costs - StocksToTrade
Price to book forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences of California launches kit to streamline high-throughput sequencing operations - Traders Union
Pacific Biosciences of California Inc (PACB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Price to sales forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Enterprise value to EBITDA forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
PACB & Blank Bio partner to advance RNA foundation models in oncology - MSN
Pacific Biosciences of California Inc (PACB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pacific Biosciences of California Inc (PACB) Institutional Confidence - TradingKey
Pacific Biosciences of California Inc - TradingKey
Pacific Biosciences of California Inc (PACB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pacific Biosciences of California Inc (PACB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pacific Biosciences of California Inc (PACB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street? - Insider Monkey
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
PacBio Announces a Private Convertible Exchange Transaction of $ - GuruFocus
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California Company Profile & Introduction - Moomoo
How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without New Analyst Targets - Yahoo Finance
Pacific Biosciences of California, Inc. 8-K Filing: 2020 Equity Incentive Plan Amendment, Stockholder Voting Results & Company Information (June 2026) – Minichart - Minichart
Pacific Biosciences (PACB) director receives 223,492 stock options at $1.58 strike - Stock Titan
Christopher Gibson (NASDAQ: PACB) receives 74,497 stock options grant - Stock Titan
PACIFIC BIOSCIENCES (PACB) director granted 223,492 stock options at $1.58 - Stock Titan
Director at Pacific Biosciences (PACB) receives 223,492 stock options grant - Stock Titan
PACB (PACB) director granted 223,492 stock options at $1.58 exercise price - Stock Titan
Pacific Biosciences reserves 16,000,000 additional shares under 2020 Equity Incentive Plan - TradingView
Director William W. Ericson granted 223,492 PACB options at $1.58 exercise price - Stock Titan
Director John Milligan receives 223,492 options at PacBio (PACB) - Stock Titan
PacBio (PACB) director Kathy Ordonez receives 223,492 stock options at $1.58 - Stock Titan
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.16%
大文字化:
|
ボリューム (24 時間):